Search results (39)
« Back to NewsKennedy scientists honoured with Royal Society Medal
16 September 2024
Professor Sir Ravinder Maini and Professor Sir Marc Feldmann have jointly received The Royal Society’s Royal Medal (Applied) for inventing anti-TNF therapy to treat rheumatoid arthritis (RA), bringing it from bench to bedside in one of the biggest success stories of modern medicine.
Kennedy Institute retreat 2024 - a whirlwind of ideas and inspiration!
9 September 2024
The Kennedy Institute retreat took place in July 2024 at the Saïd Business School, Oxford. Over two jam-packed days, attendees met new colleagues, learned about scientific advances and of course, had fun!
Celebrating two new professorships at the Kennedy Institute
25 July 2024
The Kennedy Institute at the University of Oxford recently hosted a dinner to celebrate and thank the Kennedy Trust for Rheumatology Research for its generous support and the endowment of two new professorships in translational medicine at the Institute.
The Kennedy Institute welcomes Distinguished Investigator Dr Alan Sher
4 June 2024
Alan has spent two months at the Kennedy Institute as a guest of Professor Dame Fiona Powrie. During his visit he has spent his time collaborating with researchers at the Kennedy and other departments in the University, and mentoring young investigators on their career development.
Kennedy DPhil selected for 2024 Schmidt Science Fellow program
7 May 2024
Dr Ashwin Jainarayanan has been selected to become a 2024 Schmidt Science Fellow – an honour bestowed on only 32 exceptional early career researchers worldwide.
Professor Irina Udalova appointed to the MRC’s Infections and Immunity Board
1 March 2024
The Medical Research Council’s Infections and Immunity Board (IIB) funds research into infectious human disease and disorders of the human immune system.
Oxford-ZEISS Centre of Excellence officially opened
23 February 2024
ZEISS is partnering with the University of Oxford bringing ground-breaking microscopy imaging equipment, and analysis tools, to advance the study of global health and disease.
New PI will study the mechanical forces impacting cell fate decision-making and tissue dynamics in inflammatory diseases
23 November 2023
We welcome Adrien Hallou who has joined the Kennedy Institute as a new Principal Investigator. Adrien will be establishing his lab to better understand the role of mechanical forces on cell fate decisions and tissue dynamics in inflammatory diseases, with a particular focus on inflammatory skin diseases such as psoriasis or atopic dermatitis.
Kennedy Trust for Rheumatology Research visits the Kennedy Institute
27 October 2023
The Kennedy Trust for Rheumatology Research (KTRR) visited the Kennedy Institute in early October. The Institute benefits extensively from the generous support of the KTRR and the visit was a great opportunity to share stories of our scientific successes and discuss future directions.
The Kennedy Institute celebrates support staff contributions
5 September 2023
The lunch with sandwiches, tea and strawberries was attended by staff and students and provided an opportunity to give some well-earned Long Service Awards.
New approach to nail bed injury surgery could significantly cut NHS costs
30 March 2023
According to a new Oxford study, changing clinical practice for finger injuries in children could save the NHS £720,000 per year.
The Kennedy Institute launches its single cell facility
4 January 2023
We spoke to Irina Udalova and Stephen Sansom about the Kennedy’s new single cell facility and how it will enhance research at the Institute and beyond.
Professor Michael Dustin appointed new Chair in Molecular Immunology
6 December 2022
A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.
The Kennedy’s research strongly endorsed following independent review
29 November 2022
We recently welcomed our Scientific Advisory Board (SAB) and the Kennedy Trust Scientific Review Board (TSRB) to the Institute to review our current activities and future plans.
Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease
16 November 2022
Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.
Mathematician boosts data science research at the Kennedy Institute
19 October 2022
Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.
NIHR funding for musculoskeletal and inflammatory disease research
17 October 2022
Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.
Leducq Foundation grant boosts cardiovascular research
11 October 2022
The Leducq Foundation has awarded $7.5 million to researchers at the University of Oxford and their collaborators to advance immunotherapy as a treatment for cardiovascular disease, the leading cause of death in the UK.
Welcome to the new Kennedy Trust CEO
12 July 2022
The Kennedy Trust has announced Dr Stephen Simpson as its new Chief Executive Officer from 1 July 2022.
Breakthrough in treatment for Dupuytren’s disease
30 April 2022
Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.